title: Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States.
authors.affiliation: University of Connecticut School of Pharmacy, Storrs, CT, USA. Electronic address: craig.coleman@hhchealth.org.
authors.forename: Craig I
authors.initials: CI
authors.lastname: Coleman
authors.affiliation: Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
authors.forename: Muralikrishna
authors.initials: M
authors.lastname: Tangirala
authors.affiliation: Bayer Pharma AG, Wuppertal, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Evers
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000188:drug therapy*; D000069604:Dabigatran / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D057216:Propensity Score; D012189:Retrospective Studies; D000069552:Rivaroxaban / Q000008:administration & dosage* / Q000627:therapeutic use; D020521:Stroke / Q000517:prevention & control*; D016896:Treatment Outcome; D014481:United States; D016903:Drug Monitoring
chemical_list: D000069552:Rivaroxaban; D000069604:Dabigatran
keywords: Dabigatran; Medication adherence; Non-valvular atrial fibrillation; Proportion of days covered; Rivaroxaban